title: [The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer].
abstract: From Jan. 1988 to Nov. 1992, 441 patients with bladder carcinoma were hospitalized in our department. 385 of them were treated by transurethral resection of bladder tumor (TURBT) or partial cystectomy. After surgical management, the instillation therapy with BCG, TTP or MMC, etc was used to prevent tumor recurrence in 321 patients. Follow-up for 1-7 years showed that the mortality rate was 6.9% (22/318), and the tumor recurrence rate in BCG, TTP, MMC and control groups was 18.1%, 31.2%, 29.6% and 46.1% respectively. The factors influencing the tumor recurrence and the prophylactic effect of BCG instillation immunotherapy were discussed.
authors.affiliation: Department of Urology, First Affiliated Hospital, West China University of Medical Sciences, Chengdu.
authors.forename: S
authors.initials: S
authors.lastname: Zhang
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Cheng
mesh_terms: D000283:Administration, Intravesical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011184:Postoperative Period; D001749:Urinary Bladder Neoplasms / Q000601:surgery / Q000628:therapy*
chemical_list: D001500:BCG Vaccine